Adaptive Biotechnologies Q1 Revenue Jumps 35% to $70.9M, Raises Full-Year MRD Guidance
Summary
Adaptive Biotechnologies reported robust first-quarter 2026 financial results, with total revenue increasing 35% year-over-year to $70.9 million and its key MRD revenue segment surging 53% to $67.1 million. The company also significantly narrowed its adjusted EBITDA loss to $2.5 million, demonstrating improved operational efficiency. This strong performance is further underscored by a 41% increase in clonoSEQ test volumes, driving the growth in the MRD business, which now constitutes 95% of total revenue. Crucially, management raised its full-year MRD revenue guidance to $260–$270 million, signaling strong commercial momentum and a positive outlook for its core business. This positive earnings report and upward revision of guidance are material catalysts for the stock, indicating a stronger-than-expected trajectory. Traders will be watching for continued execution on the raised guidance and further progress towards sustained profitability.
At the time of this announcement, ADPT was trading at $16.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $8.38 to $20.76. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.